Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22024919 | 0.96 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL21191715 | 0.96 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL21191655 | 0.95 | LMNA (0.41) | SMN1; SMN2L3MBTL1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL18745361 | 0.95 | LMNA (0.41) | SMN1; SMN2L3MBTL1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL19059408 | 0.95 | SMN1; SMN2 (0.42) | SMN1; SMN2L3MBTL1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL18760495 | 0.93 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL18923249 | 0.93 | LMNA (0.42) | SMN1; SMN2L3MBTL1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL18612675 | 0.93 | LMNA (0.42) | SMN1; SMN2L3MBTL1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL20980158 | 0.93 | LMNA (0.42) | SMN1; SMN2L3MBTL1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL18468195 | 0.93 | LMNA (0.42) | SMN1; SMN2L3MBTL1CYP1A2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230079631-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-16 | — | — | US | disclosed |
| US-11370763-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2022-06-28 | — | — | US | disclosed |
| US-20220009906-A1 | ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-13 | — | — | US | disclosed |
| US-20210230129-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2021-07-29 | — | — | US | disclosed |
| US-20200255428-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | PIK3CA, MAP3K1, MAP3K5 | SMN1; SMN2 4570/4885L3MBTL1 2882/4885CYP1A2 3366/4885 |
| US-20230079631-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | SMN1; SMN2 2608/4885L3MBTL1 4789/4885CYP1A2 1790/4885 |
| US-20210230129-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP3, NLRP1, IAPP | SMN1; SMN2 348/4885L3MBTL1 2700/4885CYP1A2 1891/4885 |
| US-20220009906-A1 | ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | GRK2, GRK3, GRK4 | SMN1; SMN2 3686/4885L3MBTL1 3378/4885CYP1A2 1990/4885 |
| US-20200255428-A1 | CHEMICAL COMPOUNDS | HAVCR2, HBS1L, HLA-B | SMN1; SMN2 4818/4885L3MBTL1 3122/4885CYP1A2 1118/4885 |
| US-11370763-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP3, NLRP1, IAPP | SMN1; SMN2 348/4885L3MBTL1 2700/4885CYP1A2 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.